Last reviewed · How we verify
Mezapam (MEDAZEPAM)
Mezapam (generic name: MEDAZEPAM) is a medazepam drug. It is currently in Phase 2 development.
Medazepam works by enhancing the calming effect of a neurotransmitter called GABA in the brain.
Medazepam, a small molecule belonging to the drug class of benzodiazepines, is a medication with unknown target and commercial status. Its exact mechanism of action is not well-documented, but it is believed to work by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, leading to sedative, anxiolytic, and muscle relaxant effects. Medazepam is used to treat anxiety and muscle spasms, but its approved indications and pharmacokinetic properties are unknown. As a benzodiazepine, medazepam carries a risk of dependence and withdrawal symptoms, and its use should be carefully monitored. Further research is needed to fully understand the properties and effects of medazepam.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEDAZEPAM |
|---|---|
| Drug class | medazepam |
| Target | GABA-A receptor; anion channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a busy city, with lots of signals and activity going on. GABA is like a traffic cop that helps slow down the traffic and keep things calm. Medazepam helps GABA do its job more effectively, which can lead to feelings of relaxation and reduced anxiety.
Approved indications
Common side effects
Key clinical trials
- Sedation Regimens in GI Endoscopy (EARLY_PHASE1)
- Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mezapam CI brief — competitive landscape report
- Mezapam updates RSS · CI watch RSS
Frequently asked questions about Mezapam
What is Mezapam?
How does Mezapam work?
What is the generic name of Mezapam?
What drug class is Mezapam in?
What development phase is Mezapam in?
What does Mezapam target?
Related
- Drug class: All medazepam drugs
- Target: All drugs targeting GABA-A receptor; anion channel
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing